Tafasitamab: First Approval - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/32946059/
Tafasitamab (tafasitamab-cxix; MONJUVI ® ) is an Fc-modified (i.e. two amino acid substitutions within the Fc region, resulting in increased Fcγ receptor affinity), humanized, anti-CD19 monoclonal antibody. Developed by MorphoSys AG, under a license from Xencor, it received accelerated appr ...
-
Mark FeslerApril 07, 2021This anticd19 antibody is an exciting pairing with another immunotherapeutic, revlimid, and I would expect that this antibody will gain additional treatment partners and indications both in dlbcl and other lymphoma subtypes in the coming years